Key Points
- Insider sale: Dongfang Liu sold 10,000 NUVB shares on Nov. 26 at $8.00 for $80,000, reducing their stake to 18,000 shares (a 35.71% decrease) and continuing a series of large November disposals totaling tens of thousands of shares.
- Company and market context: Nuvation Bio traded around $8 (up ~1.5%) with a $2.74B market cap; it beat quarterly EPS and revenue estimates but remains unprofitable with very negative margins, while analysts' consensus is a "Moderate Buy" with an average price target of $9.67.
Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) insider Dongfang Liu sold 10,000 shares of the firm's stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $8.00, for a total transaction of $80,000.00. Following the transaction, the insider directly owned 18,000 shares of the company's stock, valued at $144,000. The trade was a 35.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Dongfang Liu also recently made the following trade(s):
- On Wednesday, November 19th, Dongfang Liu sold 15,000 shares of Nuvation Bio stock. The stock was sold at an average price of $5.10, for a total value of $76,500.00.
- On Wednesday, November 19th, Dongfang Liu sold 15,000 shares of Nuvation Bio stock. The shares were sold at an average price of $5.10, for a total transaction of $76,500.00.
- On Monday, November 17th, Dongfang Liu sold 15,000 shares of Nuvation Bio stock. The stock was sold at an average price of $4.76, for a total value of $71,400.00.
- On Monday, November 17th, Dongfang Liu sold 15,000 shares of Nuvation Bio stock. The shares were sold at an average price of $4.76, for a total transaction of $71,400.00.
Nuvation Bio Stock Up 1.5%
NYSE NUVB traded up $0.12 during mid-day trading on Thursday, hitting $8.00. The company's stock had a trading volume of 6,971,867 shares, compared to its average volume of 11,938,983. The firm has a market capitalization of $2.74 billion, a price-to-earnings ratio of -12.49 and a beta of 1.50. The company's 50 day simple moving average is $4.54 and its 200 day simple moving average is $3.17. Nuvation Bio Inc. has a twelve month low of $1.54 and a twelve month high of $8.24. The company has a current ratio of 8.48, a quick ratio of 8.39 and a debt-to-equity ratio of 0.14.
Nuvation Bio (NYSE:NUVB - Get Free Report) last announced its earnings results on Monday, November 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01. The company had revenue of $13.12 million for the quarter, compared to analysts' expectations of $7.48 million. Nuvation Bio had a negative return on equity of 54.99% and a negative net margin of 813.07%. Analysts anticipate that Nuvation Bio Inc. will post -0.36 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of brokerages have recently weighed in on NUVB. Wall Street Zen upgraded Nuvation Bio from a "sell" rating to a "hold" rating in a research note on Sunday, August 17th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Nuvation Bio in a report on Wednesday, October 8th. B. Riley assumed coverage on shares of Nuvation Bio in a research note on Wednesday, November 19th. They set a "buy" rating and a $12.00 price target for the company. Jefferies Financial Group initiated coverage on shares of Nuvation Bio in a research note on Tuesday, September 30th. They issued a "buy" rating and a $10.00 target price for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Nuvation Bio in a report on Friday, September 19th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $9.67.
Get Our Latest Research Report on Nuvation Bio
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. Parallel Advisors LLC lifted its stake in Nuvation Bio by 51.9% during the third quarter. Parallel Advisors LLC now owns 7,597 shares of the company's stock worth $28,000 after purchasing an additional 2,597 shares during the last quarter. LCM Capital Management Inc grew its position in Nuvation Bio by 29.2% during the third quarter. LCM Capital Management Inc now owns 15,500 shares of the company's stock valued at $57,000 after acquiring an additional 3,500 shares during the last quarter. Mackenzie Financial Corp raised its stake in shares of Nuvation Bio by 38.8% during the third quarter. Mackenzie Financial Corp now owns 15,746 shares of the company's stock worth $58,000 after acquiring an additional 4,400 shares in the last quarter. Integrated Wealth Concepts LLC lifted its holdings in shares of Nuvation Bio by 21.9% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 24,610 shares of the company's stock worth $91,000 after acquiring an additional 4,419 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Nuvation Bio by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 108,547 shares of the company's stock valued at $191,000 after purchasing an additional 4,608 shares during the last quarter. Institutional investors own 61.67% of the company's stock.
Nuvation Bio Company Profile
(
Get Free Report)
Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
